ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS

This Executive Order, signed by Donald J. Trump on April 18, 2026, directs the federal government to accelerate the research, approval, and accessibility of psychedelic drugs (such as ibogaine compounds) to combat the crisis of serious mental illness and rising suicide rates, particularly among veterans.The summary of the order’s key components is as follows:The order identifies a failure in traditional psychiatric therapies to curb suicide rates, which the text notes have rebounded following the COVID-19 pandemic. It specifically highlights the "tragedy" of veteran suicides. To address this, the administration’s policy is to fast-track innovative research into psychedelic drugs that have shown "Breakthrough Therapy" potential in clinical studies.Priority Vouchers: The FDA is directed to provide "National Priority Vouchers" to speed up the review of psychedelic drugs designated as Breakthrough Therapies.Expanded Access: The order mandates the establishment of a pathway for eligible patients to access these substances under the Right to Try Act, removing regulatory hurdles (such as Schedule I handling restrictions) for physicians and researchers.The Department of Health and Human Services (HHS) is directed to allocate at least $50 million via the Advanced Research Projects Agency for Health (ARPA-H). This money is intended to support state governments that are already developing or enacting programs to advance psychedelic treatments.The order compels the HHS, FDA, and Department of Veterans Affairs (VA) to collaborate with the private sector. The goal is to:Increase participation in clinical trials.Share real-world evidence and data to help the FDA evaluate and approve these drugs more quickly.Prioritize data sharing specifically to help veterans access new treatments.The Attorney General is directed to initiate a review of any Schedule I substance that successfully completes Phase 3 clinical trials. The goal is to ensure that if a psychedelic drug is approved by the FDA, its "rescheduling" (moving it out of the most restrictive drug category) happens as quickly as possible so it can be legally prescribed.The order frames the move toward psychedelic medicine as a necessary, innovative step to "save lives and reverse the crisis of serious mental illness" where standard medications have failed.1. Purpose and Policy2. Accelerated FDA Review and "Right to Try"3. Federal Funding for States4. Inter-Agency and Private Sector Collaboration5. Expedited ReschedulingConclusion